亿帆医药创新药F-627完成对美市场首批发货

Core Viewpoint - The company Yifan Pharmaceutical has successfully completed the first shipment of its innovative drug F-627 to the U.S. market, marking a significant milestone in its international expansion [1] Group 1: Product Launch - F-627, also known as Ryzneuta, is the world's first third-generation long-acting G-CSF drug for increasing white blood cell counts [1] - The drug has received approval for sale in multiple regions, including China, the U.S., the EU, and Brazil [1] Group 2: Market Expectations - Based on current order conditions, the company anticipates shipping approximately 40,000 units overseas by 2025 [1] - The drug has been successfully included in China's medical insurance directory following negotiations in 2023 [1]